Criteria Systemic Sclerosis Panel

Casandra

Casandra Test Code AR84817Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 3000479CPT Codes 83516, 86039, 86235

Criteria Systemic Sclerosis Panel

Also known as: SSC PANEL

Clinical Use

Order Test

Use

The Criteria Systemic Sclerosis Panel is indicated for patients with distinct features of systemic scleroderma/sclerosis (SSc). The presence of Scl-70 antibodies (also referred to as topoisomerase I, topo-I or ATA) is considered diagnostic for systemic sclerosis (SSc). RNA Polymerase III antibodies are used as an aid in the diagnosis of systemic sclerosis with increased incidence of skin involvement and renal crisis. Antinuclear antibodies (ANA) are a hallmark feature of systemic autoimmune rheumatic diseases, such as SARDs, and while they lack diagnostic specificity, they are associated with a variety of diseases, including cancers and autoimmune conditions.

Special Instructions

For a more comprehensive panel that includes U3 RNP (fibrillarin), PM/Scl-100, and U1RNP, refer to Systemic Sclerosis, Comprehensive Panel (3000480). Collect serum in a serum separator tube (SST) and separate from cells as soon as possible or within 2 hours of collection.

Limitations

Negative results do not necessarily rule out the presence of SSc. If clinical suspicion remains, additional testing may be needed. Scl-70 antibodies alone are detected in about 20% of SSc patients and have also been reported in patients with systemic lupus erythematosus, which may lead to a false-positive result. RNA polymerase III IgG antibody results can also yield false-positives due to non-specific binding of immune complexes.

Test Details

FDA Approved